This workshop will address non-alcoholic fatty liver disease (NAFLD), which affects over 25% of the world’s population. Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), which can inflame and damage the liver to the point of advanced fibrosis or cirrhosis, increasing the chances of liver failure, liver cancer or even death. (These risks can be more than twice as high for people living with diabetes, obesity, or high blood pressure).1 More accurate and frequent assessment of prognosis of disease progression risk is needed for patients with advanced fibrosis due to NASH.
The evolution of non-invasive liver fibrosis tests has created the opportunity to improve the assessment of risk of progression to cirrhosis and liver-related events, helping to ensure NASH patients get the care they need while reducing healthcare costs.
Learning Objectives:
- Educate on the current growing burden of disease due to NAFLD/NASH
- Learn how non-invasive testing can help identify patients with advanced fibrosis due to NASH at risk of disease progression
- Understand how clinicians can implement available patient pathways to improve referrals and decrease costs
Speaker:
J.M. Schattenberg
University Medical Center Mainz, Mainz, Germany
In the rapidly evolving landscape of diagnostic testing, Siemens Healthineers recognizes the value of ongoing education for both clinicians and laboratory professionals. This webinar is part of our Clinical Experts on Demand webinar series, offering a suite of educational webinars led by industry leaders discussing how innovations in laboratory diagnostics are transforming patient care delivery.
